What Is Calcium Folinate? Uses, Action, and Side Effects

Calcium folinate is a pharmaceutical form of a naturally occurring B vitamin (folate) that the body can use immediately, without the conversion steps ordinary folic acid requires. It goes by several names: leucovorin, folinic acid, and citrovorum factor are all the same molecule, with “calcium folinate” simply describing its calcium salt formulation. Hospitals and oncology clinics rely on it for two seemingly opposite jobs, and the fact that a single drug can both amplify a chemotherapy agent and protect healthy cells from a different one makes it one of the more unusual tools in modern medicine.

Two Opposite Jobs With One Molecule

Calcium folinate’s dual role in cancer care can sound contradictory until you look at the chemistry involved. In one setting it makes a chemotherapy drug more lethal to tumors; in another it shields normal tissues from a completely different chemotherapy drug’s toxicity. The distinction comes down to which drug it is paired with and what it does inside the cell once it arrives.

When combined with the chemotherapy drug 5-fluorouracil (5-FU), calcium folinate increases the intracellular pool of a specific folate form that locks 5-FU’s active metabolite onto its target enzyme, thymidylate synthase. That enzyme is essential for making one of the building blocks of DNA. Calcium folinate stabilizes a three-way molecular complex between the folate cofactor, the 5-FU metabolite, and thymidylate synthase, keeping the enzyme shut down for longer and making DNA synthesis inhibition more rapid and sustained.¹ Without added folinate, tumor cells that happen to have low natural folate levels can partly escape the drug’s effect. With folinate on board, those cells are more reliably killed.²

When paired instead with methotrexate, the picture flips. Methotrexate works by blocking the body’s ability to process folate, which starves fast-dividing cells of the raw materials they need. The trouble is that normal fast-dividing tissues like the gut lining, bone marrow, and mouth mucosa get starved too. Calcium folinate bypasses the blockade methotrexate creates, flooding healthy cells with the reduced folate they need to survive. This is called “leucovorin rescue,” and the timing of that rescue turns out to matter a great deal.

Leucovorin Rescue After High-Dose Methotrexate

High-dose methotrexate is a backbone treatment for several cancers, particularly certain leukemias and lymphomas. After the methotrexate infusion finishes, clinicians wait a set number of hours and then begin giving calcium folinate to protect normal tissues. The window between too early (which could blunt the anti-cancer effect) and too late (which risks serious toxicity) has been studied carefully.

A pediatric review found that starting leucovorin rescue at 30 to 36 hours after the methotrexate infusion began was safe, while delaying it to 42 to 48 hours led to considerable toxicity, particularly when higher methotrexate doses were used. The authors recommended starting rescue no later than 36 hours from the start of methotrexate at doses in the range of 5 to 6 grams per square meter of body surface area.³

In adults with non-Hodgkin lymphoma, a crossover trial compared starting rescue at 18 hours versus 24 hours. Both groups achieved effective methotrexate concentrations in the blood. The 24-hour group did see somewhat higher rates of low platelet counts and severe neutropenia (about 48% versus 35% for low platelets, and about 35% versus 21% for severe neutropenia), but these were manageable, and the researchers concluded that waiting until 24 hours offered greater anti-tumor benefit with acceptable side effects for most adult patients.⁴ In practice, the exact timing protocol varies by institution and by the specific methotrexate dose being used, and blood levels of methotrexate are monitored to guide how long and how aggressively rescue continues.

Boosting 5-FU in Colorectal Cancer

The combination of 5-FU with a folinate salt is one of the most established regimens in colorectal cancer treatment.⁵ Several well-known chemotherapy protocols, including the “Mayo Clinic regimen” and the FOLFOX and FOLFIRI regimens that add oxaliplatin or irinotecan, all include leucovorin as a standard component. In these regimens, leucovorin is not treating cancer on its own. It is a pharmacological amplifier that makes 5-FU hit harder by ensuring that the molecular trap holding the drug on its target enzyme stays locked in place.

The strength of this amplification comes with a tradeoff. A prospective study of 243 colorectal cancer patients on the Mayo Clinic regimen (5-FU plus leucovorin) found that about 13% required hospitalization for chemotherapy-related toxicity. The most common severe problems were low white blood cell counts with fever (roughly 9%), severe mouth sores (about 10%), and severe diarrhea (about 8%). Five patients, roughly 2%, died from treatment-related causes, typically after the first cycle.⁶ These numbers reflect an older bolus-dosing schedule; newer infusional regimens tend to produce somewhat different side-effect profiles. But the broader point holds: because calcium folinate amplifies 5-FU’s effects on all dividing cells, not just tumor cells, it intensifies toxicity to fast-turnover tissues like the gut and bone marrow alongside its anti-cancer benefit.

Protecting Against Low-Dose Methotrexate Side Effects in Rheumatoid Arthritis

Outside of cancer, methotrexate at much lower weekly doses is the most widely used drug for rheumatoid arthritis. Even at these low doses, it can cause nausea, mouth sores, elevated liver enzymes, and sometimes anemia. Supplementing with either folic acid or folinic acid (calcium folinate) helps counteract these side effects without undermining the drug’s ability to control joint inflammation.

A Cochrane systematic review of the evidence found that folate supplementation during low-dose methotrexate therapy cut gastrointestinal side effects like nausea and vomiting by roughly a quarter, reduced abnormal liver enzyme elevations by about 77%, and lowered the rate of patients stopping methotrexate for any reason by around 61%.⁷ A double-blind trial specifically testing leucovorin found that side effects were reported at nearly half the rate in the leucovorin group compared to placebo, and far fewer patients on leucovorin dropped out due to intolerable side effects, about 14% versus 35%. Disease activity at one year was similar in both groups, meaning the leucovorin did not blunt methotrexate’s anti-inflammatory effect.⁸

A separate 48-week trial compared folic acid, folinic acid, and placebo head to head. Methotrexate was discontinued for toxicity in 38% of placebo patients, 17% of folic acid patients, and only 12% of folinic acid patients, largely because liver enzyme problems were much rarer in both supplementation groups.⁹ In everyday practice, most rheumatologists prescribe inexpensive folic acid rather than folinic acid for this purpose, since both appear protective. Folinic acid is sometimes reserved for patients who still have significant side effects despite folic acid supplementation.

Cerebral Folate Deficiency and Autism Research

A less widely known use of calcium folinate involves rare neurological conditions in which folate cannot reach the brain properly. In cerebral folate deficiency, folate levels in spinal fluid are low even when blood folate is normal, typically because the transport protein that carries folate across the blood-brain barrier is dysfunctional or blocked by autoantibodies. Because folinic acid can enter the brain through an alternate transport route (the reduced folate carrier), oral supplementation can restore normal folate levels in the central nervous system.¹⁰

This mechanism has attracted interest in autism spectrum disorder (ASD) research, since a subset of children with ASD test positive for autoantibodies against the folate receptor. Studies ranging from case series to a double-blind placebo-controlled trial suggest that leucovorin can improve particular symptoms in children with ASD, especially those who carry these folate receptor autoantibodies.¹¹ In children with confirmed cerebral folate deficiency and neurological symptoms, oral folinic acid supplements normalized spinal fluid folate and led to partial or complete clinical recovery over 12 months in one study.¹² This remains an active area of research, and leucovorin for ASD is not yet standard practice outside of children with a confirmed folate transport defect.

How the Body Absorbs and Processes It

Calcium folinate can be given intravenously, intramuscularly, or by mouth. When taken orally, blood levels of the drug and its main active metabolite (5-methyltetrahydrofolate) typically peak one to two hours after a dose. An interesting pharmacokinetic quirk is that absorption appears to saturate at doses above about 15 milligrams: at higher oral doses, neither the peak blood concentration nor the steady-state level rises proportionally. This means that doubling an oral dose above that threshold does not double the amount that reaches the bloodstream.¹³ For high-dose leucovorin rescue in cancer settings, intravenous administration is preferred precisely because it bypasses this absorption ceiling.

Commercially available leucovorin is a 50/50 mix of two mirror-image forms: the biologically active “l” form (also called 6S-leucovorin or levoleucovorin) and the inactive “d” form. Levoleucovorin calcium is also sold on its own, at half the dose of standard leucovorin, since it contains only the active half. A pharmacokinetic comparison in volunteers found no significant differences between the two formulations in terms of how the active folate form and its metabolite behaved in the body, confirming that the inactive d-form essentially passes through without interfering.¹⁴ Cell-based research has confirmed that the protective effect against antifolate drugs depends on the l-form and on the presence of the reduced folate carrier on cell surfaces.¹⁵

Side Effects When Used Alone Versus in Combination

Calcium folinate by itself is remarkably well tolerated. It is, after all, a form of a B vitamin. When given alone or as a low-dose supplement alongside methotrexate for arthritis, the main reported adverse effects are mild and uncommon: occasional nausea, rash, or a low-grade allergic reaction. Serious reactions to leucovorin itself, in the absence of chemotherapy, are rare.

The side-effect profile changes dramatically when leucovorin is used as part of a 5-FU-based cancer regimen, because the whole point of adding it is to make 5-FU more potent. Early clinical experience made this clear when severe, sometimes life-threatening toxicity was observed in trials combining leucovorin with 5-FU.¹⁶ The toxicities are essentially amplified versions of 5-FU’s own side effects:

• Diarrhea: Can become severe and dehydrating, sometimes requiring hospitalization and intravenous fluids.
• Mucositis: Painful inflammation of the mouth and throat lining that can make eating and drinking difficult.
• Myelosuppression: Lowered blood counts, particularly white blood cells (neutropenia), which raises infection risk. Neutropenic fever is one of the more dangerous complications.
• Skin reactions: Hand-foot syndrome (painful redness and peeling on the palms and soles) and other dermatologic effects.

As noted earlier, a prospective study of the Mayo Clinic 5-FU/leucovorin regimen put the hospitalization rate for severe toxicity at about 13%, with a 2% death rate.⁶ Newer infusional schedules and protocol refinements have improved the safety landscape, but the fundamental reality remains that calcium folinate, by doing its intended job of amplifying 5-FU, also amplifies the collateral damage to healthy tissues.

Emergency Use in Methotrexate Toxicity

Sometimes high-dose methotrexate causes acute kidney injury, which prevents the body from clearing the drug normally. Methotrexate levels stay dangerously elevated, and without intervention, severe damage to the bone marrow, liver, and mucous membranes can follow. In these emergencies, high-dose leucovorin is a first-line intervention. It floods the body with reduced folate to protect as many normal cells as possible while the kidneys recover.

When kidney dysfunction is severe and methotrexate clearance is critically delayed, leucovorin is often combined with glucarpidase, an enzyme that directly breaks down methotrexate in the bloodstream. A study of this combination found that early intervention with leucovorin and glucarpidase was highly effective, while delaying rescue was associated with severe toxicity and death.¹⁷ Increased hydration, high-dose leucovorin, and glucarpidase together are usually sufficient to allow kidney recovery without dialysis.¹⁸ Speed matters here: every hour of delay worsens outcomes.

Drug Interactions Worth Knowing About

Calcium folinate interacts with a handful of other medications in clinically important ways. The best-documented interaction is with the anti-seizure drug phenytoin. Folinic acid (like folic acid) can lower phenytoin levels in the blood, potentially leading to breakthrough seizures. A case report described a patient whose phenytoin became ineffective during concurrent chemotherapy that included calcium folinate; once the chemotherapy course ended, phenytoin levels returned to normal.¹⁹ Anyone taking phenytoin or a related anti-epileptic drug should have their levels monitored more closely if calcium folinate is started.

A less obvious but clinically relevant interaction involves trimethoprim-sulfamethoxazole, a common antibiotic. Trimethoprim works by blocking a folate pathway in bacteria, and flooding the system with reduced folate could theoretically undermine that mechanism. In practice, most clinicians manage this by adjusting timing rather than avoiding leucovorin altogether, but it is something prescribers keep in mind, especially in immunocompromised patients who may be on both drugs simultaneously.

The Vitamin B12 Question

A longstanding caution around any form of supplemental folate is that it might mask vitamin B12 deficiency. The concern originated in the 1940s, when patients with pernicious anemia (a condition caused by B12 deficiency) were treated with high-dose folic acid before B12 was widely available. Some of these patients developed neurological complications, and the assumption took hold that the folic acid itself was causing or accelerating nerve damage.

A detailed reexamination of those historical case reports concluded that the likely cause of the neurological problems was simply untreated B12 deficiency progressing over time, not the folic acid making things worse. The daily folic acid doses used in those cases, often 5 to 20 milligrams, were far higher than modern supplementation levels, and the patients had no access to B12 treatment. The authors argued that the historical record does not provide compelling evidence that folic acid (or, by extension, folinic acid) directly causes neurologic complications in people with low B12 status.²⁰ That said, the regulatory upper limit for folic acid was set partly on the basis of that old concern, and clinicians still routinely check B12 levels before starting high-dose folate supplementation as a practical precaution.

Practical Differences Between Brand Names and Forms

You may encounter calcium folinate under its generic name leucovorin calcium, as the branded product levoleucovorin (which contains only the active l-isomer), or simply as “folinic acid.” All refer to the same functional molecule, though levoleucovorin is dosed at half the milligram amount of racemic leucovorin because it does not contain the inactive mirror-image form. Hospitals sometimes switch between formulations based on availability or cost, which can create confusion if the dose numbers look different. A 100-milligram dose of standard leucovorin and a 50-milligram dose of levoleucovorin deliver the same amount of biologically active folate.

Calcium folinate is available in both injectable and oral forms. For cancer protocols involving high doses, injectable forms predominate because of the oral absorption ceiling described earlier. For lower-dose rescue after moderate methotrexate doses, or for rheumatoid arthritis supplementation, oral tablets are often sufficient. Storage matters for the injectable form: reconstituted solutions have limited stability and are typically prepared fresh by hospital pharmacies.